U.S. Volumetric Infusion Pumps Market Size, Share, and Growth Forecast 2026 - 2033

The U.S. volumetric infusion pumps market is expected to be valued at US$ 560.4 million in 2026 and is projected to reach US$ 747.4 million, growing at a CAGR of 4.2% between 2026 and 2033. Rising chemotherapy infusion volumes and continued hospital replacement of legacy pump fleets are key factors supporting this growth trajectory.

The American Cancer Society (ACS) projects more than two million new cancer diagnoses annually in the U.S., many requiring precisely dosed intravenous chemotherapy, while the U.S. Food and Drug Administration (FDA) continues to emphasize infusion pump safety and device modernization. These converging clinical and regulatory factors are reinforcing hospital and clinic investment in volumetric infusion pump technology nationwide.

Drivers - Rising Chemotherapy and Oncology Infusion Volumes

The rising volume of chemotherapy administration across U.S. hospitals and infusion centers is a key growth driver for the market. The American Cancer Society (ACS) estimates that more than two million new cancer cases are diagnosed annually nationwide, creating significant demand for precisely controlled intravenous chemotherapy delivery. The Oncology Nursing Society (ONS) continues to publish updated chemotherapy administration safety standards supporting programmable infusion technologies to reduce dosing errors during cytotoxic drug delivery.

As outpatient oncology infusion centers expand nationwide to accommodate rising cancer treatment volumes, hospitals and ambulatory infusion clinics continue investing in peristaltic and cassette-based volumetric pump fleets capable of delivering precise, continuous infusion rates. This trend is reinforcing procurement demand for manufacturers such as B. Braun Melsungen AG and ICU Medical, Inc. across the expanding oncology care infrastructure, including community-based infusion centers serving patients closer to home.

Regulatory Emphasis on Infusion Pump Safety and Smart Pump Adoption

Heightened regulatory scrutiny of infusion pump safety continues to support hospital replacement of legacy pump fleets with modern volumetric systems. The FDA has maintained a dedicated infusion pump safety improvement initiative for over a decade, citing recurring device malfunction reports through its Manufacturer and User Facility Device Experience (MAUDE) database as a basis for continued oversight. The Institute for Safe Medication Practices (ISMP) actively promotes smart pump technology equipped with dose-error reduction software as a medication safety best practice for U.S. hospitals.

This sustained regulatory and clinical focus on safety is encouraging health systems to accelerate fleet modernization cycles, replacing aging analog and semi-automated pumps with programmable volumetric systems that integrate dose-checking software. The trend is supporting consistent capital equipment demand across hospital pharmacy and nursing procurement budgets, particularly as biomedical engineering departments prioritize standardized, networked pump fleets over aging mixed-vendor inventories.

Restraints - High Initial and Maintenance Costs

The capital-intensive nature of volumetric infusion pumps limits adoption among smaller clinics and independent ambulatory surgical centers operating on constrained budgets. Comprehensive smart pump systems require substantial upfront acquisition costs alongside recurring software licensing, drug library maintenance, and biomedical engineering support expenses. The Healthcare Financial Management Association (HFMA) has noted persistent capital budget constraints among smaller and rural healthcare facilities, limiting their ability to modernize infusion pump fleets at the same pace as larger, well-capitalized hospital systems. These financial constraints can temper broader market penetration across resource-constrained care settings, particularly independent clinics without access to group purchasing organization pricing advantages.

Device Recalls and Reliability Concerns Affecting Purchasing Confidence

Periodic infusion pump recalls continue to affect purchasing confidence and extend procurement decision cycles across U.S. hospitals. The FDA has issued multiple Class I recalls for infusion pump systems in recent years, citing software malfunctions and dosing accuracy concerns. These recall events prompt hospital biomedical engineering departments to conduct more extensive vendor evaluation processes before committing to fleet-wide procurement, potentially delaying replacement cycles and creating short-term demand fluctuations despite consistent clinical requirements for volumetric infusion technology across oncology, pediatric, and analgesia care settings. Procurement committees increasingly consider vendor track records alongside device performance specifications when evaluating replacement purchases.

Opportunities - Expansion of Cassette and Piston-Based Precision Infusion Technology

Cassette and piston-based infusion pumps are gaining traction, presenting an opportunity for manufacturers to expand precision drug delivery portfolios beyond traditional peristaltic systems. Cassette-based platforms offer enhanced dosing accuracy for high-potency and low-volume medications, an increasingly important capability as pediatric and neonatal care protocols require tighter dosing tolerances.

The American Academy of Pediatrics (AAP) continues to emphasize precise, weight-based medication dosing standards for neonatal intensive care, reinforcing clinical demand for accurate infusion technologies. Manufacturers such as Fresenius Kabi AG and Smiths Medical are investing in cassette and piston-based pump portfolios with enhanced dosing precision and drug library customization to address growing hospital demand for accurate medication delivery across vulnerable patient populations during the forecast period.

Interoperability with Electronic Health Records and Smart Hospital Systems

The accelerating adoption of interoperable, EHR-integrated infusion pump systems presents an opportunity for vendors expanding connected pump technology. The Office of the National Coordinator for Health Information Technology (ONC) continues to promote healthcare interoperability standards that support data exchange between infusion pumps and electronic health record systems.

Companies including B. Braun Melsungen AG and ICU Medical, Inc. have expanded wireless-enabled pump platforms capable of updating drug libraries and transmitting infusion data directly to hospital information systems. As health systems increasingly prioritize connected medication administration and safety, vendors offering interoperable volumetric pump ecosystems can address demand from hospitals modernizing their medication safety infrastructure over the coming years, particularly as healthcare organizations place greater emphasis on integrated clinical workflows and connected medical devices.

Product Insights

Peristaltic pumps are the leading product segment, holding around 82% share of the U.S. volumetric infusion pumps market in 2026. This dominance reflects peristaltic technology's broad clinical versatility, cost-effectiveness, and established compatibility with standard intravenous administration sets across virtually every hospital department. The Association for the Advancement of Medical Instrumentation (AAMI) continues to reference peristaltic pump design in its infusion device performance standards, reinforcing widespread clinical familiarity and confidence.

Established manufacturers including B. Braun Melsungen AG and Becton, Dickinson and Company maintain extensive peristaltic pump product lines with broad hospital fleet compatibility, reinforcing procurement standardization around this technology, even as cassette and piston-based systems are gaining traction.

Cassette/piston pumps represent the fastest-growing product segment, owing to their precise fluid delivery, improved dosing control, and suitability for applications requiring accurate administration of low-volume or high-potency medications. Their increasing adoption in pediatric and neonatal care, where weight-based dosing and tight flow-rate control are particularly important, is supporting segment growth. Growing demand for precision infusion technologies across specialized clinical settings is further contributing to adoption.

Application Insights

Chemotherapy/oncology represents the leading application segment, holding about 36% share of the the U.S. volumetric infusion pumps market in 2026. This leadership is attributed to the substantial and rising volume of cancer treatment procedures performed annually, with the American Cancer Society (ACS) estimating over two million new cancer diagnoses each year, many requiring multi-cycle intravenous chemotherapy regimens.

Clinical safety standards published by the Oncology Nursing Society (ONS) mandate programmable volumetric pump use for cytotoxic drug administration to minimize dosing error risk. This sustained oncology treatment volume continues to reinforce the segment’s leading position in the market.

Southeast U.S. Volumetric Infusion Pumps Market Insights

The Southeast U.S. is likely to lead the market by holding around 27% share in 2026, reflecting the area’s comparatively higher cancer incidence rates documented by the CDC across states including Kentucky, Mississippi, and Louisiana. Extensive hospital networks across Florida, Georgia, and the Carolinas, combined with growing outpatient oncology infusion center development, continue to reinforce the zone’s leading position in volumetric infusion pump procurement nationwide.

Southwest U.S. Volumetric Infusion Pumps Market Insights

The Southwest U.S. represents the fastest-growing market, propelled by rapid population expansion across Texas and Arizona, as tracked by the U.S. Census Bureau. Growing hospital and ambulatory oncology infusion center infrastructure investment across the area, combined with rising cancer treatment demand, continues to accelerate volumetric infusion pump procurement in the coming years.

Northeast U.S. Volumetric Infusion Pumps Market Insights

The Northeast U.S. is expected to hold a significant share of the market in 2026, supported by a dense concentration of academic medical centers and comprehensive cancer centers across New York, Massachusetts, and Pennsylvania. Established procurement relationships with major infusion pump manufacturers and consistently high oncology treatment volumes across the zone’s hospital systems continue to sustain stable demand for volumetric infusion pumps.

Midwest U.S. Volumetric Infusion Pumps Market Insights

The Midwest U.S. is projected to hold a considerable share to the market in 2026, supported by established integrated health systems across Ohio, Illinois, and Michigan. Consistent oncology, pediatric, and surgical infusion volumes, combined with steady hospital fleet modernization initiatives, continue to support stable demand for peristaltic and cassette-based volumetric infusion pumps across the zone’s hospitals and clinics.

The U.S. volumetric infusion pumps market is moderately consolidated, with global medical device leaders such as B. Braun Melsungen AG, Fresenius Kabi AG, and ICU Medical, Inc. competing alongside established manufacturers including Becton, Dickinson and Company, Terumo Corporation, and Smiths Medical. Competitive strategy centers on smart pump software innovation, dose-error reduction system enhancement, and expanding EHR interoperability capabilities.

Key differentiators include drug library customization depth, wireless connectivity, and biomedical engineering support infrastructure. Emerging business model trends favor pump-as-a-service and managed equipment leasing arrangements, allowing hospitals to modernize infusion fleets without large upfront capital expenditure while ensuring continuous software and safety updates.

Key Industry Developments

• In April 2025, ICU Medical announced the introduction of its new category of infusion devices after receiving U.S. FDA clearance for the Plum Solo and Plum Duo Precision IV Pumps. The newly launched volumetric infusion pumps were developed to deliver accurate and reliable intravenous medication and fluid administration while simplifying clinical workflows.